search for: chemotherapy

..., treatment, treatment, function(uft) cbind(ifelse(uft<=1,1,0),ifelse(uft>1,1,0)), failcode=1, cencode=0, na.action=na.omit, gtol-06, maxiter) fit1 where: rel.t = time to event (in years) rel.s = status , =1 if disease relapse, =2 if death from non disease related cause (toxicity of previous chemotherapy), =0 if alive & not in relapse treatment = binary covariate (value: 0 or 1) representing the treatment to test (different from chemotherapy above, with no known toxicity) I have not yet added other covariates in the model. this script gave me the following result: > fit1 <- crr(relcmp.t...

...+ presentation variables + treatment variables( X_t) y = \beta_(a3).age + \BETA_(p3).X_(p) + \BETA_(t3).X_t Presentation variables include variables such as tumor grade, tumor size, etc... the physician cannot interfer with these variables. Treatment variables include variables such as chemotherapy, radiation, surgical margins (a surrogate for adequate surgery). I have used cph for the models and restricted cubic splines (Design library) for age. I have noted that the effect of age decreases from model 1 to 3. I would like to compare the effect of age on the outcome across the different...

...atment, treatment, function(uft) cbind(ifelse(uft<=1,1,0),ifelse(uft>1,1,0)), failcode=1, cencode=0, na.action=na.omit, gtol-06, maxiter) fit1 where: rel.t = time to event (in years) rel.s = status , =1 if disease relapse, =2 if death from non disease related cause (toxicity of previous chemotherapy), =0 if alive & not in relapse treatment = binary covariate (value: 0 or 1) representing the treatment to test (different from chemotherapy above, with no known toxicity) I have not yet added other covariates in the model. this script gave me the following result: > fit1 <- crr(relc...

...lution is: aggregate(.~ id, lapply(df, as.character), FUN = function(x)paste(sort(x), collapse = ''), na.action = na.pass) Could somebody EXPLAIN HOW IT WORKS? I mean Henrique saved my investigation indeed. However, considering the fact, that I am about to perform investigation of cancer chemotherapy in 500 patients, it would be nice to know what I am actually doing. 1. All help says about LHS in formulas like '.~id' is that it's name is "dot notation". And not a single word more. Thus, I have no clue, what dot in that formula really means. 2. help says: Note that ?past...

Hello All, Recently developed the code below for graphing patterns of chemotherapy administration. As someone just starting to use R in their work, I managed to figure out some parts of the code but needed help with others. setwd("N:/Regimen Coding/0906/Plots Test") getwd() TestData <- structure(list(profile_key = c(1, 1, 1, 1, 1, 2, 2, 2, 2, 2, 2, 3, 3, 3, 3, 3)...

...as I'm completely new to R - having started using it yesterday. However I am already warming to its lack of 'proper' GUI... I like being able to rerun a command by editing one parameter easily... try and do that in a Excel Chart Wizzard! I eventually want to use it to analyse some chemotherapy response / survival data. That data will not be mature and so my interest is in using it to deliver predictions of what mature data may produce by using Weibull Regression However for now I've borrowed a dataset from the BMJ (CSV tabs seperated version here: http://www.wittongilbert.free-...

...t; cbind(ifelse(uft<=1,1,0),ifelse(uft>1,1,0)), failcode=1, > cencode=0, na.action=na.omit, gtol-06, maxiter) > fit1 > > where: > rel.t = time to event (in years) > rel.s = status , =1 if disease relapse, =2 if death from non disease > related cause (toxicity of previous chemotherapy), =0 if alive & > not in relapse > treatment = > binary covariate (value: 0 or 1) representing the treatment to test > (different from chemotherapy above, with no known toxicity) > I have not yet added other covariates in the model. > > > this script gave me the follow...

Hi al, I have a dataset (see attached), which basically involves 4 treatments for a chemotherapy drug. Samples were taken from 2 biopsy locations, and biopsy were taken at 2 time points. So each subject has 4 data points (from 2 biopsy locations and 2 time points). The objective is to study treatment difference.? I used lme to fit a mixed model that uses "biopsy.site nested within pid&qu...

Hi Guys, My first post here. I have recently installed RH9 and am having some rather wierd problems that make me suspect file corruption. After some useage the machine locked up hard when trying to use 3d graphics (I have a radeon 7200 with dri enabled). After this happened occasionally the system refuses to boot- it stops at the apm line of the kernel boot process. I tried looking at my hard

...ng from lack of diagnostic accuracy, I think we have to work hard to use this technology to help them, if we can. I think we can, even now. What if I offer, in my clinic, a service for cancer patients to compare their affy data to an existing set of data, to predict their prognosis or response to chemotherapy? I think people will line up out the door for such a service. Knowing what we as a group of array analyzers know, wouldn't we all want this kind of service available if we or a loved one got cancer? Can our programs deal with 1,000 .cel files? 10,000 files? I think our programs are prett...

I have an error for a simple optimization problem. Is there anyone knowing about this error? lambda1=-9 lambda2=-6 L<-function(a){ s2i2f<-(exp(-lambda1*(250^a)-lambda2*(275^a-250^a)) -exp(-lambda1*(250^a)-lambda2*(300^a-250^a))) logl<-log(s2i2f) return(-logl)} optim(1,L) Error in optim(1, L) : function cannot be evaluated at initial parameters Thank you in advance -- View this

...files utilising next generation sequencing (Hodgkinson et al Nature Medicine, June 2014). We will for the first time using advanced molecular analysis define CTC heterogeneity and examine differences in CTC genomic profiles of small cell lung cancer (SCLC) patients who are sensitive or resistant to chemotherapy, an approach that will ultimately lead to biomarker signatures for therapy selection. 2 x Postdoctoral Scientists (Biomarker Statisticians): The successful candidates will be involved in biomarker driven clinical trial design, the development of statistical methods tailored to biomarker analysis (...

>> We are ready to spend more than 10.000 euros to help Xen to support Windows >> 2000 >I asked a Microsoft sales guy about ports of Windows and got this quote >forwarded from the Microsoft Research guys in Cambridge >"The XenoXP work is not currently under active development. Whilst >there is no *technical* reason that it can''t be done (and it would Ok

A user asked me about this and I can't figure it out. tmt% R R Under development (unstable) (2018-04-09 r74565) -- "Unsuffered Consequences" Copyright (C) 2018 The R Foundation for Statistical Computing Platform: x86_64-pc-linux-gnu (64-bit) > library(survival) > data(cgd0) Warning message: In data(cgd0) : data set ?cgd0? not found ---- The data set is present and can be

Dear List, I am (again) looking at meta-regression as a way to refine meta-analytic results. What I want to do is to assess the impact of some fixed factors on the results of a meta-analysis. Some of them may be crossed with the main factor of the meta-analysis (e. g. clinical presentation of a disease, defining subgroups in each of the studies under analysis), some of them may be a grouping

...39; is that it's name is "dot notation". And not a single word more. Thus, I have no clue, what dot in that formula really means. Conclusion: 1. It's a magic. 2. You definitely saved my investigation. (When I've started I had no idea it would be so difficult to arrange those chemotherapy cycles in dataframe, although I dare to call myself pharmacoepidemiologist (which sounds rather funny after that story)) 3. THANK YOU!!!!!! Sincerely yours Denis Kazakiewicz Belarus ? ???, 21/01/2011 ? 18:37 -0200, Henrique Dallazuanna ????: > Just change the FUN function: > > aggregate...